{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:42:11Z","timestamp":1792017731230,"version":"4.4.0"},"reference-count":111,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cgh.2023.02.005","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T23:08:13Z","timestamp":1676848093000},"page":"2076-2087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":132,"title":["New Treatment Paradigms in Primary Biliary Cholangitis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-6037","authenticated-orcid":false,"given":"Cynthia","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Manns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.02.005_bib1","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/gast.2000.20197","article-title":"Epidemiology and natural history of primary biliary cirrhosis in a US community","volume":"119","author":"Kim","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib2","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","article-title":"Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment","volume":"16","author":"Lu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","article-title":"Diagnosis and management of primary biliary cholangitis","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/cgh.2003.50014","article-title":"When is liver biopsy needed in the diagnosis of primary biliary cirrhosis?","volume":"1","author":"Zein","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/hep.28859","article-title":"Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis","volume":"65","author":"Dahlqvist","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cld.2022.06.004","article-title":"Autoantibodies in primary biliary cholangitis","volume":"26","author":"Leung","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2023.02.005_bib8","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.14309\/ajg.0000000000000765","article-title":"Role of antinuclear antibodies in primary biliary cholangitis","volume":"115","author":"Levy","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib9","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/ng.627","article-title":"Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis","volume":"42","author":"Liu","year":"2010","journal-title":"Nat Genet"},{"key":"10.1016\/j.cgh.2023.02.005_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/hep.24355","article-title":"Epithelial cell specificity and apotope recognition by serum autoantibodies in primary biliary cirrhosis","volume":"54","author":"Rong","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.23783","article-title":"Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in primary biliary cirrhosis","volume":"52","author":"Lleo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-0039-1697617","article-title":"The pathogenesis of primary biliary cholangitis: a comprehensive review","volume":"40","author":"Lleo","year":"2020","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2023.02.005_bib13","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/hep.20907","article-title":"Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients","volume":"42","author":"Gershwin","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.02.005_bib15","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJM199105303242204","article-title":"A\u00a0multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis: UDCA-PBC Study Group","volume":"324","author":"Poupon","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.02.005_bib16","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib17","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib18","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib19","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib21","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2018.12.028","article-title":"Effects of age and sex of response to ursodeoxycholic acid and transplant-free survival in patients with primary biliary cholangitis","volume":"17","author":"Cheung","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib22","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/apt.15533","article-title":"Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response","volume":"50","author":"Murillo Perez","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.005_bib23","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1542-3565(04)00465-3","article-title":"Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?","volume":"2","author":"Yang","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib24","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis","volume":"43","author":"Wesierska-Gadek","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","article-title":"Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib26","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/hepr.12423","article-title":"Autoantibody status and histological variables influence biochemical response to treatment and long-term outcomes in Japanese patients with primary biliary cirrhosis","volume":"45","author":"Nakamura","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cgh.2023.02.005_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/liv.14688","article-title":"Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis","volume":"41","author":"Haldar","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.02.005_bib28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cld.2022.06.014","article-title":"Liver transplantation for primary biliary cholangitis","volume":"26","author":"Martin","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2023.02.005_bib29","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib30","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1478-3231.1999.tb00020.x","article-title":"Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid","volume":"19","author":"Angulo","year":"1999","journal-title":"Liver"},{"key":"10.1016\/j.cgh.2023.02.005_bib31","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1478-3231.2011.02678.x","article-title":"Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis","volume":"32","author":"Momah","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.02.005_bib32","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib33","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib34","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib35","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib36","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib37","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib38","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.14309\/ajg.0000000000001285","article-title":"A\u00a0comparison of prognostic scores (Mayo, UK-PBC, and GLOBE) in primary biliary cholangitis","volume":"116","author":"Goet","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/gutjnl-2014-308351","article-title":"Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study","volume":"65","author":"Trivedi","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.005_bib40","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib41","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.cgh.2020.08.006","article-title":"Measurement of gamma glutamyl transferase to determine risk of liver transplantation or death in patients with primary biliary cholangitis","volume":"19","author":"Gerussi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis: 2021 update","volume":"75","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib44","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/j.jhep.2022.06.017","article-title":"Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis","volume":"77","author":"Corpechot","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib45","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/hep.31017","article-title":"Liver injury in patients with cholestatic liver disease treated with obeticholic acid","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib46","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A\u00a0randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib47","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib48","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.02.005_bib49","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","article-title":"Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study","volume":"4","author":"Trauner","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib50","article-title":"UK-wide multicenter evaluation of second-line therapies in primary biliary cholangitis","author":"Abbas","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib51","article-title":"Real-world experience with obeticholic acid in patients with primary biliary cholangitis","volume":"3","author":"D\u2019Amato","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2023.02.005_bib52","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep4.1518","article-title":"Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis","volume":"4","author":"Roberts","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.cgh.2023.02.005_bib53","first-page":"1545","article-title":"Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls","volume":"77","author":"Murillo Perez","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib54","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1111\/liv.14429","article-title":"Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis","volume":"40","author":"Pares","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.02.005_bib55","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis","volume":"39","author":"Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib56","article-title":"Efficacy and safety of bezafibrate alone or in combination with ursodeoxycholic acid in primary biliary cholangitis: systematic review and meta-analysis","author":"Khakoo","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.02.005_bib57","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib58","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.02.005_bib59","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/hep.31613","article-title":"Improved markers of cholestatic liver injury in patients with primary biliary cholangitis treated with obeticholic acid and bezafibrate","volume":"73","author":"Smets","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib60","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.005_bib61","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/liv.14871","article-title":"Safety of fibrates in cholestatic liver diseases","volume":"41","author":"Carrion","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.02.005_bib62","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib63","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jhep.2020.09.011","article-title":"A\u00a0placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","volume":"74","author":"Hirschfield","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib64","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib65","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.26365","article-title":"Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study","volume":"58","author":"Mells","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib66","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.cgh.2018.12.007","article-title":"Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom","volume":"17","author":"Hegade","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib67","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","author":"Mayo","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.02.005_bib68","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1542-3565(03)00134-4","article-title":"Natural history of pruritus in primary biliary cirrhosis","volume":"1","author":"Talwalkar","year":"2003","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib69","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/gut.49.2.276","article-title":"Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant","volume":"49","author":"Vleggaar","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2023.02.005_bib70","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1056\/NEJM196109072651004","article-title":"The treatment of pruritus and hypercholesteremia of primary biliary cirrhosis with cholestyramine","volume":"265","author":"Van Itallie","year":"1961","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.02.005_bib71","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0016-5085(66)80071-9","article-title":"Cholestyramine for long term relief of the pruritus complicating intrahepatic cholestasis","volume":"50","author":"Datta","year":"1966","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib72","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib73","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for Itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib74","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials","volume":"26","author":"Khurana","year":"2006","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.02.005_bib75","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib76","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/apt.14579","article-title":"Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study","volume":"47","author":"Webb","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2023.02.005_bib77","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1111\/j.1572-0241.2003.08662.x","article-title":"Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis","volume":"98","author":"Browning","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2023.02.005_bib78","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib79","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000360515","article-title":"Pathogenesis of primary biliary cirrhosis and its fatigue","volume":"32","author":"Griffiths","year":"2014","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2023.02.005_bib80","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1007\/s10620-019-06009-3","article-title":"Symptom burden and treatment response in patients with primary biliary cholangitis (PBC)","volume":"65","author":"Kaps","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.02.005_bib81","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.20276","article-title":"Quality of life in patients with primary biliary cirrhosis","volume":"40","author":"Poupon","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib82","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2010.02.022","article-title":"Loss of capacity to recover from acidosis in repeat exercise is strongly associated with fatigue in primary biliary cirrhosis","volume":"53","author":"Hollingsworth","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib83","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17474124.2021.1844565","article-title":"Managing cognitive symptoms and fatigue in cholestatic liver disease","volume":"15","author":"Phaw","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib84","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.04.017","article-title":"The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study","volume":"59","author":"Carbone","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib85","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/PL00009532","article-title":"Primary biliary cirrhosis, sicca complex, and dysphagia","volume":"12","author":"Mang","year":"1997","journal-title":"Dysphagia"},{"key":"10.1016\/j.cgh.2023.02.005_bib86","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ajo.2004.02.010","article-title":"Therapeutic effect of cevimeline on dry eye in patients with Sjogren\u2019s syndrome: a randomized, double-blind clinical study","volume":"138","author":"Ono","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.cgh.2023.02.005_bib87","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1136\/ard.2002.003889","article-title":"Oral pilocarpine for the treatment of ocular symptoms in patients with Sjogren\u2019s syndrome: a randomised 12 week controlled study","volume":"62","author":"Tsifetaki","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2023.02.005_bib88","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.bbadis.2011.02.014","article-title":"PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation","volume":"1812","author":"Varga","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cgh.2023.02.005_bib89","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.bbadis.2010.12.021","article-title":"Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease","volume":"1812","author":"Claudel","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.cgh.2023.02.005_bib90","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/hep.27744","article-title":"Fibrates and cholestasis","volume":"62","author":"Ghonem","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib91","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A\u00a0phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib92","first-page":"71A","article-title":"Long-term safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC): 2-year results from a long-term study","volume":"74","author":"Mayo","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib93","doi-asserted-by":"crossref","first-page":"S1122","DOI":"10.1016\/S0016-5085(22)62695-7","article-title":"Seladelpar treatment of patients with primary biliary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival","volume":"162","author":"Hansen","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2023.02.005_bib94","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.02.005_bib95","article-title":"ENHANCE: safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC)\u2014a phase 3 international, randomized placebo-controlled trial","volume":"72","author":"Hirschfield","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib96","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","article-title":"Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology","volume":"19","author":"Fuchs","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib97","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A\u00a0randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib98","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jhep.2021.08.025","article-title":"Proof-of-concept study to evaluate the safety and efficacy of saroglitazar in patients with primary biliary cholangitis","volume":"76","author":"Vuppalanchi","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib99","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41423-022-00858-1","article-title":"NADPH oxidase family proteins: signaling dynamics to disease management","volume":"19","author":"Begum","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.cgh.2023.02.005_bib100","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/hep.21093","article-title":"Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in\u00a0vivo","volume":"43","author":"Zhan","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib101","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2019.04.012","article-title":"Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice","volume":"71","author":"Nishio","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib102","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/S0618-8278(19)30002-7","article-title":"Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: interin efficacy results of a phase 2 clinical trial","volume":"70","author":"Dalekos","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib103","first-page":"782A","article-title":"Setanaxib reduces liver stiffness and fatigue in patients with primary biliary cholangitis and liver stiffness \u22659.6 kPa: post hoc analyses from a randomized, controlled, phase 2 trial","volume":"74","author":"Levy","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.02.005_bib104","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s40257-022-00710-2","article-title":"Cholestatic itch: our current understanding of pathophysiology and treatments","volume":"23","author":"Vander Does","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib105","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus","author":"Levy","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib106","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.02.005_bib107","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.02.005_bib108","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.cld.2022.06.013","article-title":"Novel therapies in primary biliary cholangitis: what is in the pipeline?","volume":"26","author":"Buchanan-Peart","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2023.02.005_bib109","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00281-022-00909-9","article-title":"Cellular senescence in the cholangiopathies: a driver of immunopathology and a novel therapeutic target","volume":"44","author":"Trussoni","year":"2022","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.cgh.2023.02.005_bib110","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.cld.2022.06.009","article-title":"Evaluation and management of pruritus in primary biliary cholangitis","volume":"26","author":"Dull","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.cgh.2023.02.005_bib111","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2020-000579","article-title":"Home-based exercise in patients with refractory fatigue associated with primary biliary cholangitis: a protocol for the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) feasibility trial","volume":"8","author":"Freer","year":"2021","journal-title":"BMJ Open Gastroenterol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523001106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523001106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:43:56Z","timestamp":1761543836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523001106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":111,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1542356523001106"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.02.005","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Treatment Paradigms in Primary Biliary Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}